Development of TN-301 – A Highly Selective HDAC6 Inhibitor for HFpEF Treatment

Time: 8:30 am
day: Day One

Details:

• Explore the discovery of HDAC6 as a novel target for heart failure through a high content screening approach in iPS-derived
cardiomyocytes
• Hear how TN-301 has activity in in vivo HFpEF models and works through multiple mechanisms of action including blocking fibrosis, inflammation, and modulating metabolic pathways
• Learn about IND-enabling studies that are being carried out for TN-301 and are advancing this compound to clinical development for the
treatment of HFpEF

Speakers: